Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tricyclic GyrB/ParE (TriBE) Inhibitors: A New Class of Broad-Spectrum Dual-Targeting Antibacterial Agents

26 Dec 2013

Abstract excerpt

Increasing resistance to every major class of antibiotics and a dearth of novel classes of antibacterial agents in development pipelines has created a dwindling reservoir of treatment options for serious bacterial infections. The bacterial type IIA topoisomerases, DNA gyrase and topoisomerase IV, are validated antibacterial drug targets with multiple prospective drug binding sites, including the catalytic site...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Cancer therapeutics and mechanisms
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24386374
DOI: 10.1371/journal.pone.0084409

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tricyclic GyrB/ParE (TriBE) Inhibitors: A New Class of Broad-Spectrum Dual-Targeting Antibacterial AgentsPMID 24386374Read ↗

Rational design of balanced dual-targeting antibiotics with limited resistance.Semantic proximity Read ↗

Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitorsSemantic proximity Read ↗

Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical UseSemantic proximity Read ↗

Novel Dual-Targeting Benzimidazole Urea Inhibitors of DNA Gyrase and Topoisomerase IV Possessing Potent Antibacterial Activity: Intelligent Design and Evolution through the Judicious Use of Structure-Guided Design and Stucture−Activity RelationshipsSemantic proximity Read ↗

Advancement of GyrB Inhibitors for Treatment of Infections Caused by Mycobacterium tuberculosis and Non-tuberculous MycobacteriaSemantic proximity Read ↗

DNA topoisomerase I and DNA gyrase as targets for TB therapySemantic proximity Read ↗

DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogensSemantic proximity Read ↗

Interactions between Zoliflodacin and Neisseria gonorrhoeae Gyrase and Topoisomerase IV: Enzymological Basis for Cellular TargetingSemantic proximity Read ↗

Type II Topoisomerases as Targets for Quinolone Antibacterials Turning Dr. Jekyll into Mr. HydeSemantic proximity Read ↗

Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance.Semantic proximity Read ↗

Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.Semantic proximity Read ↗

Developments on antibiotics for multidrug resistant bacterial Gram-negative infectionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.